The immune system’s role in lung cancer risk
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
List view / Grid view
Articles
Pioneering the advancement of pre-targeted radioimmunotherapies
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
Optimising CRISPR gene editing of hard-to-transfect cells
CRISPR has transformed gene editing, but still presents challenges in hard-to-transfect cells, such as pluripotent stem cells and primary cells.1 The key to obtaining successful transfection in these cells lies in innovative workflows. Here Georges Müller, CEO and cofounder of SEED Biosciences, shares his perspective on why focusing on editing…
Identifying vascular disease associations
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
HIF inhibition: a potential therapeutic approach for cancers
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
How nucleolar stress accelerates aging in mice
Dr Fernández-Capetillo shares his insights from a recent study conducted at the CNIO, elucidating how the expression of (PR)arginine-rich peptides affects ribosomal protein translation and accumulation, and how accelerated aging can be alleviated.
Using AI to predict metastatic behaviour of NSCLC
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
Finding the right CDMO partner for cell line development
The commercial production of recombinant proteins, such as antibodies and enzymes, relies on generating and maintaining specific cell lines designed to produce these specialised molecules. However, the creation of cell lines is a technically demanding and time-consuming process. For this reason, many businesses seek partnerships with contract development and manufacturing…
Investigating antipsychotics in a Parkinson’s disease psychosis model
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
Women in Stem with Dr Christine Schuberth-Wagner
Dr Christine Schuberth-Wagner serves as Chief Scientific Officer at CatalYm. She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in the immuno-oncology space. She has established a track record as a successful leader and entrepreneur in the biotech…
Unlocking the potential of natural products in drug discovery
Natural products play an underappreciated role in drug discovery. Tandem mass spectrometry (MS/MS)-based metabolomics coupled with machine learning is allowing new, highly diverse molecules from natural products to be identified, revealing bioactive compounds and pinpointing promising drug targets. The additional dimension provided by trapped ion mobility (TIMS) enables researchers to…
Women in STEM with Delphine Guyon-Gellin
Join us for our Women in STEM series with Delphine Guyon-Gellin, Chief Business Development Officer at Osivax. She joined the company in 2018 with 15 years of experience in vaccine business and strategy. Prior to her work at Osivax, Delphine worked as a strategic consultant for leading pharmaceutical companies, helping…
Developing an mRNA therapy for Duchenne muscular dystrophy
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
The advancement of drug-free immunotherapy
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
Optimised antibody panels for CTC and rare cell enumeration
Despite significant strides in cancer research, metastasis remains the primary cause of cancer-related mortality globally. Joby Chesnick and Tracey Long, from the Digital Biology Group and Life Science Group, respectively, at BioRad Laboratories, reveal how investigation into circulating tumour cells (CTCs) and other rare cell types has led to the…